AstraZeneca Expands U.S. Investment Plan
LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...
Shares of AstraZeneca PLC AZN rallied 1.54% to £101.44 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to 8,030 ...
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...
Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
AstraZeneca Pharma India on Wednesday said its net profit declined by 27 per cent on-year to Rs 38 crore in the second ...
Profit after tax came in ₹38.4 crore in Q2 of FY25, a recovery from a net loss of ₹11.8 crore in the first quarter of this ...
Andrew Berens gave his rating based on several factors, including AstraZeneca’s strong financial performance in the third quarter of 2024. The company reported total revenues of $13.565 billion, ...
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback